MedTrace Logo

Pharmacokinetics of Telavancin in Normal and Obese Subjects

NCT02753855 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-11-02

No results posted yet for this study

Summary

The purpose of this study is to characterize plasma and urinary concentrations of telavancin following intravenous administration of a single dose of telavancin in healthy subjects who are normal weight, overweight, and obese.

Conditions

  • Healthy

Interventions

DRUG

Telavancin

A single dose of telavancin as a 1-hour intravenous infusion

Sponsors & Collaborators

  • Theravance Biopharma

    collaborator INDUSTRY

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Keith A. Rodvold, Pharm.D. · University of Illinois at Chicago

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02753855 on ClinicalTrials.gov